<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00445120</url>
  </required_header>
  <id_info>
    <org_study_id>LACTO2</org_study_id>
    <secondary_id>Eudract number 2007-000209-31</secondary_id>
    <nct_id>NCT00445120</nct_id>
  </id_info>
  <brief_title>Lactobacillus Rhamnosus GG Oral Treatment Efficacy on Vernal Keratoconjunctivitis Treatment</brief_title>
  <official_title>Multicenter, Randomised, Double Masked, Controlled Studies on the Efficacy of Lactobacillus Rhamnosus GG Treatment in Preventing Vernal Keratoconjunctivitis VKC) Relapses.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Campus Bio-Medico University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Genova</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Padova</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Campus Bio-Medico University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This interventional study aims to evaluate the efficacy of oral administration of
      Lactobacillus Rhamnosus GG in preventing relapses of ocular inflammation in Vernal
      Keratoconjunctivitis (VKC) patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vernal keratoconjunctivitis (VKC) is a chronic allergic disease, characterised by ocular
      surface inflammation lasting all year with seasonal relapses. Active phases of VKC are
      characterised by intense ocular symptoms and require treatment with topical steroids to
      control inflammation and corneal damage. To date, safe and effective therapies in preventing
      relapses of VKC are not available. Recently, the use of oral administration of probiotics for
      allergic diseases have been proposed. No data are available on the effects of probiotics on
      ocular allergies. This multicenter, double-masked, randomised, controlled clinical trial will
      allow to obtain more data on the efficacy of oral treatment with Lactobacillus Rhamnosus GG
      in patients affected by VKC. Patients with VKC will be treated with Lactobacillus Rhamnosus
      GG or placebo in addition to ketotifen fumarate 0.025% eye drops (standard treatment). The
      number of relapses per year, signs and symptoms of the disease, total symptom score (TSyS),
      total sign score (TSS), biochemical and molecular parameters will be evaluated at different
      time points.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate a difference in the number of relapses of ocular inflammation for year between Lactobacillus Rhamnosus GG and placebo treated groups. Relapses will be defined as at least 100% increase of the sum of hyperemia,</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences of specific symptoms and signs, TSyS, TSS, Quick questionnaire subscales,biochemical and molecular parameters will be evaluated at baseline, after 1, 3 and 6 months of treatment and after 1 month of treatment discontinuation</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Vernal Keratoconjunctivitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactobacillus Rhamnosus GG</intervention_name>
    <description>patients are treated with oral Lactobacillus Rhamnosus GG once daily for six months</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo (sugar)</intervention_name>
    <description>Placebo will be administered to patients once daily for six months</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of VKC performed on the basis of personal and family history of systemic
             allergic diseases, clinical examination (presence of conjunctival tarsal and/or limbal
             papillae) and presence of eosinophils in the conjunctival scraping.

        Exclusion Criteria:

          -  Contact lens wearers,

          -  Patients affected by other ocular diseases,

          -  Patients subjected to ocular surgery in the preceding 6 months,

          -  Patients under eye drop or systemic treatments for other diseases,

          -  Patients enrolled in experimental trials in the preceding 6 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefano Bonini, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Campus Bio-Medico</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Genova</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Padua</name>
      <address>
        <city>Padua</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Campus Bio-Medico</name>
      <address>
        <city>Rome</city>
        <zip>00155</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Kalliomäki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet. 2001 Apr 7;357(9262):1076-9.</citation>
    <PMID>11297958</PMID>
  </reference>
  <reference>
    <citation>Kalliomäki M, Salminen S, Poussa T, Arvilommi H, Isolauri E. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet. 2003 May 31;361(9372):1869-71.</citation>
    <PMID>12788576</PMID>
  </reference>
  <reference>
    <citation>Boyle RJ, Tang ML. The role of probiotics in the management of allergic disease. Clin Exp Allergy. 2006 May;36(5):568-76. Review.</citation>
    <PMID>16650040</PMID>
  </reference>
  <reference>
    <citation>Peng GC, Hsu CH. The efficacy and safety of heat-killed Lactobacillus paracasei for treatment of perennial allergic rhinitis induced by house-dust mite. Pediatr Allergy Immunol. 2005 Aug;16(5):433-8.</citation>
    <PMID>16101937</PMID>
  </reference>
  <reference>
    <citation>Viljanen M, Savilahti E, Haahtela T, Juntunen-Backman K, Korpela R, Poussa T, Tuure T, Kuitunen M. Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo-controlled trial. Allergy. 2005 Apr;60(4):494-500.</citation>
    <PMID>15727582</PMID>
  </reference>
  <reference>
    <citation>Bonini S, Bonini S, Lambiase A, Marchi S, Pasqualetti P, Zuccaro O, Rama P, Magrini L, Juhas T, Bucci MG. Vernal keratoconjunctivitis revisited: a case series of 195 patients with long-term followup. Ophthalmology. 2000 Jun;107(6):1157-63.</citation>
    <PMID>10857837</PMID>
  </reference>
  <reference>
    <citation>Leonardi A. Vernal keratoconjunctivitis: pathogenesis and treatment. Prog Retin Eye Res. 2002 May;21(3):319-39. Review.</citation>
    <PMID>12052387</PMID>
  </reference>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2007</study_first_submitted>
  <study_first_submitted_qc>March 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2007</study_first_posted>
  <last_update_submitted>January 28, 2009</last_update_submitted>
  <last_update_submitted_qc>January 28, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2009</last_update_posted>
  <responsible_party>
    <name_title>Stefano Bonini</name_title>
    <organization>University of Rome Campus Bio-Medico</organization>
  </responsible_party>
  <keyword>Vernal keratoconjunctivitis</keyword>
  <keyword>probiotic</keyword>
  <keyword>Lactobacillus Rhamnosus GG</keyword>
  <keyword>Children</keyword>
  <keyword>Clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

